Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Uran Boom: Die Bullen starten durch - spektakuläre Kursgewinne möglich
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E17K | ISIN: US6412558800 | Ticker-Symbol: NLZ0
München
30.04.24
08:04 Uhr
4,340 Euro
0,000
0,00 %
1-Jahres-Chart
NEUROMETRIX INC Chart 1 Jahr
5-Tage-Chart
NEUROMETRIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,0004,14017:09
ACCESSWIRE
479 Leser
Artikel bewerten:
(2)

RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.

  • Stock trades significantly below its net cash per share.
  • The board is arguably in breach of their fiduciary responsibility to protect shareholder value. Operating any capital raise at current price is grossly irresponsible and against shareholders best interests.
  • The board must immediately cancel their at-the-market program, and begin a process of returning substantial cash to shareholders in order to halt this egregious value destruction.

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / On March 4, 2024, Ryan Siegal of RS Fund Management LLC filed a Schedule 13D/A which included a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter states that given where the stock is trading and with a review in progress, the Board must exercise their duty and authority to stop raising capital - immediately . This strategy is an indefensible, unjustified, stripping of shareholder value for purposes of paying the CEO, management, and directors: placing their interests ahead of shareholders. Ryan also argues for returning capital immediately, as a first step toward a liquidation: the best option for shareholders.

The Board of Directors should know better, given that they include:

Bradley M. Fluegel: Wharton School, University of Pennsylvania, Lecturer

David E. Goodman: California MD

Nancy E. Katz: 2010 Bayer Senior VP

David Van Avermaete: 2004 Johnson and Johnson Lifescan President

A full copy of the letter can be found below:

CONTACT:

Ryan Siegal
ryan@rsfundmanagement.com

March 4, 2024

To the Board of Directors of NeuroMetrix:

As of December 31, 2023, the company, NeuroMetrix had approximately $18.0 million of net cash and approximately 1.5 million shares outstanding, which equates to approximately $12.00 of net cash per share. The stock trades at ~$4.00. The company has a surplus of cash, well beyond operations for the indefinite future (including the conclusion of their strategic review).

We believe the only correct business decisions are below to advance shareholder value.

1)Effective Immediately, halt all capital raising, inclusive of at the market offerings: raising capital is a terrible destruction of shareholder value. The company should even consider buying back shares in the open market.

2)In the interim, and by the end of March: Return the higher of $7.00 in cash or 70% of net assets while assessing options for the remainder of the company.

It is abundantly clear to us that it would be in shareholders' best interests if you were to immediately liquidate the company . As the company, in our view, has no legitimate prospects for positive returns in any of its business lines (and if they did/do, we still think those would be better sold to the highest bidder: for a CVR or inconsequential cash value)

We believe shareholders would overwhelmingly support our suggestion to immediately liquidate, as well as the above two swift actions, and to begin a process of returning all proceeds to shareholders- the clearest way to maximize shareholder value.

We hope you will accept our advice and immediately announce an immediate cancellation of capital raising plan, a return of capital or liquidation without us having to take additional public action. If you have any questions, please do not hesitate to contact us.

Sincerely,

Ryan Siegal
RS FUND LP

SOURCE: RS Fund Management LLC



View the original press release on accesswire.com

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2024 ACCESSWIRE
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.